Bar-Or, Amit
O’Brien, Susan M.
Sweeney, Michael L.
Fox, Edward J.
Cohen, Jeffrey A.
Article History
Accepted: 5 July 2021
First Online: 9 August 2021
Declarations
:
: The authors received no honoraria related to the development of this publication. Medical writing support and the open access fee was funded by Novartis Pharmaceuticals Corporation.
: Amit Bar-Or has participated as a speaker in meetings sponsored by, and received consulting fees and/or grant support from, Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, and Sanofi-Genzyme. Susan O’Brien has received consulting fees from Amgen, Astellas Pharma, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences, Vaniam Group, AbbVie, and Alexion; grant support from Kite Pharma, Regeneron, and Acerta Pharma; and grant support and consulting fees from Gilead Sciences, Pharmacyclics, TG Therapeutics, Pfizer, and Sunesis Pharmaceuticals. Michael L. Sweeney has received speaking fees and served on advisory boards for Novartis and Genentech. Edward J. Fox has received compensation for research, consulting, speakers' bureau, and/or advisory work from AbbVie, Alexion, Biogen, Bristol-Myers Squibb, Chugai, EMD Serono, Genentech/Roche, MedDay, Novartis, Sanofi Genzyme, Teva, and TG Therapeutics. Jeffrey A. Cohen has received personal compensation for consulting from Adamas, Atara, Bristol-Myers Squibb, Convelo, MedDay, and Mylan; and for serving as an Editor of Multiple Sclerosis Journal.
: Not applicable.
: Not applicable.
: All authors made substantial contributions to the manuscript concept/design, critically reviewed and revised the manuscript drafts and drafts of the corresponding video, and provided final approval of the manuscript and video.
: Not applicable.
: Not applicable.
: Not applicable.